Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 327

1.

Specific and durable elimination of antibody to donor HLA antigens in renal-transplant patients.

Zachary AA, Montgomery RA, Ratner LE, Samaniego-Picota M, Haas M, Kopchaliiska D, Leffell MS.

Transplantation. 2003 Nov 27;76(10):1519-25.

PMID:
14657698
2.
3.

Comparison of combination Plasmapheresis/IVIg/anti-CD20 versus high-dose IVIg in the treatment of antibody-mediated rejection.

Lefaucheur C, Nochy D, Andrade J, Verine J, Gautreau C, Charron D, Hill GS, Glotz D, Suberbielle-Boissel C.

Am J Transplant. 2009 May;9(5):1099-107. doi: 10.1111/j.1600-6143.2009.02591.x.

4.

Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients.

Montgomery RA, Zachary AA, Racusen LC, Leffell MS, King KE, Burdick J, Maley WR, Ratner LE.

Transplantation. 2000 Sep 27;70(6):887-95.

PMID:
11014642
5.
6.

Excellent renal allograft survival in donor-specific antibody positive transplant patients-role of intravenous immunoglobulin and rabbit antithymocyte globulin.

Mai ML, Ahsan N, Wadei HM, Genco PV, Geiger XJ, Willingham DL, Taner CB, Hewitt WR, Grewal HP, Nguyen JH, Hughes CB, Gonwa TA.

Transplantation. 2009 Jan 27;87(2):227-32. doi: 10.1097/TP.0b013e31818c962b.

PMID:
19155977
7.
8.

Posttransplant immunosuppression in highly sensitized patients.

Akalin E.

Contrib Nephrol. 2009;162:27-34. doi: 10.1159/000170810. Epub 2008 Oct 31. Review.

PMID:
19001811
9.

Posttransplant therapy using high-dose human immunoglobulin (intravenous gammaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action.

Jordan SC, Quartel AW, Czer LS, Admon D, Chen G, Fishbein MC, Schwieger J, Steiner RW, Davis C, Tyan DB.

Transplantation. 1998 Sep 27;66(6):800-5.

PMID:
9771846
10.

Successful transplantation across positive B-cell cross-match in deceased donor renal transplants.

Goh A, Oei E, Vathsala A.

Transplant Proc. 2012 Jan;44(1):193-9. doi: 10.1016/j.transproceed.2011.12.046.

PMID:
22310613
11.

The acceptable reactive crossmatch (ARC), post-transplant monitoring, and their impact on kidney transplantation: a single center experience.

Leone JP, Bowers V, Baliga R, Sanders C, LeFor W, Becker D, Thompson D, Resto-Ruiz S, Lopez-Cepero M.

Clin Transpl. 2011:373-9.

PMID:
22755434
12.
13.
14.

Clinical relevance of pretransplant donor-specific HLA antibodies detected by single-antigen flow-beads.

Amico P, Hönger G, Mayr M, Steiger J, Hopfer H, Schaub S.

Transplantation. 2009 Jun 15;87(11):1681-8. doi: 10.1097/TP.0b013e3181a5e034.

PMID:
19502960
15.
16.
17.

Acceptable donor-specific antibody levels allowing for successful deceased and living donor kidney transplantation after desensitization therapy.

Reinsmoen NL, Lai CH, Vo A, Cao K, Ong G, Naim M, Wang Q, Jordan SC.

Transplantation. 2008 Sep 27;86(6):820-5. doi: 10.1097/TP.0b013e3181856f98.

PMID:
18813107
18.

Successful renal transplantation across simultaneous ABO incompatible and positive crossmatch barriers.

Warren DS, Zachary AA, Sonnenday CJ, King KE, Cooper M, Ratner LE, Shirey RS, Haas M, Leffell MS, Montgomery RA.

Am J Transplant. 2004 Apr;4(4):561-8.

19.

Blood levels of donor-specific human leukocyte antigen antibodies after renal transplantation: resolution of rejection in the presence of circulating donor-specific antibody.

Higgins R, Hathaway M, Lowe D, Lam F, Kashi H, Tan LC, Imray C, Fletcher S, Zehnder D, Chen K, Krishnan N, Hamer R, Briggs D.

Transplantation. 2007 Oct 15;84(7):876-84.

PMID:
17984841
20.

Presensitization: the problem and its management.

Jordan SC, Pescovitz MD.

Clin J Am Soc Nephrol. 2006 May;1(3):421-32. Epub 2006 Apr 12. Review.

Supplemental Content

Support Center